What makes these medications truly remarkable is their capacity to modulate crucial molecular pathways and neurochemical processes intricately linked to cognitive function and the development of Alzheimer’s disease, such as the reduction of amyloid-β levels, tau hyperphosphorylation, and the amelioration of inflammation and oxidative stress. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.